HIV Protease Passages — Study Notes

HIV Protease: Overview

HIV protease is an aspartyl protease that uses an aspartate side chain in catalytic peptide-bond cleavage.
Structure: small enzyme, forms a homodimer consisting of 99 residue subunits.
Therapeutic strategy: structure-based drug design targeting HIV protease to treat HIV infection.
Key functional detail: protease cleaves specific peptide bonds within viral polyproteins to activate mature viral components.
Figure references (from transcript):
- Figure 1 shows a portion of the peptide cleaved by HIV protease.
- Figure 2 shows a potent HIV protease inhibitor (compound one).
Implication for drug design: leveraging knowledge of the enzyme’s active site to design transition-state analogs and optimized inhibitors.

Compound One: Properties and Metabolism

Compound one is a potent HIV protease inhibitor designed via structure-based approaches.
In vivo half-life: $t_{1/2} = 1.8 ext{ h}$ .
Major metabolic route: metabolism primarily by CYP3A (an enzyme in the cytochrome P450 family).
Major metabolite: results from deacylation of CH $_2$ R groups attached to the piperazine-containing system (piperazinyl/piperazine-related moiety).
Major adverse effect with prolonged use: formation of kidney stones composed of calcium oxalate, CaC $2$ O $4$ .

Role of Compound One: Mechanism and Drug-Action Classification

Compound one is used to treat HIV infection because of its ability to act as an antagonist (choice B).
Explanation of terms:
- Agonist: activates a receptor to produce a biochemical response.
- Antagonist: blocks the biochemical function of the target protein by binding to it.
- Placebo: inert; has no biochemical/physiological effect.
- Catalyst: a substance that increases the rate of a chemical reaction; HIV protease is a catalyst in its natural substrate turnover, but an inhibitor blocks this catalytic function.
Correct reasoning: compound one inhibits HIV protease’s catalytic activity, i.e., it acts as an antagonist toward the protease function (not as an agonist).

Drug Design and Derivative Development

Researchers used knowledge of:
- The HIV protease active site anatomy
- Metabolic pathways involved in the destruction/desactivation of compound one
Objective of derivatives: modify properties to increase potency and extend half-life.
Approach: design and synthesize several derivatives of compound one to optimize pharmacokinetics and pharmacodynamics while maintaining inhibitory activity.

Question 1: Short Answers and Explanations

Question: Compound one is used to treat HIV infection based on its ability to act as a(n):
- A) an agonist
- B) an antagonist
- C) a placebo
- D) a catalyst
Correct answer: B.
Rationale: Agonists activate receptors; compound one inhibits HIV protease, blocking its catalytic activity, so it functions as an antagonist rather than an agonist or placebo. It is not a catalyst.

Question 2: Stereoisomerism of Compound One

Question: How many stereoisomers exist for compound one?
- A) 8
- B) 16
- C) 32
- D) 64
Correct answer: C (32).
Explanation:
- The number of stereoisomers for a molecule with n chiral centers is given by $N = 2^{n}.$
- Compound one has five chiral centers, so $N = 2^{5} = 32.$
- Note: The transcript also mentions examples for other counts (e.g., 3 chiral centers → 8, 4 chiral centers → 16, 6 chiral centers → 64), illustrating the same rule.

Question 3: Why kidney stones form with compound one

Question: Why do kidney stones form in some individuals treated with compound one?
- A) $Ca^{2+} + ext{C}2 ext{O}4^{2-} > K_{sp}$
- B) $Ca^{2+} + ext{C}2 ext{O}4^{2-} > K_{sp}$ (their formatting varies in the transcript but essentially the same idea)
- C) $Ca^{2+} + ext{C}2 ext{O}4^{2-} < K_{sp}$
- D) $Ca^{2+} + ext{C}2 ext{O}4^{2-} < K_{sp}$ (variation in the written options)
Correct answer: B (precipitation occurs when the reaction quotient Q exceeds the solubility product constant K $_{sp}$ ).
Explanation:
- The expression for the reaction quotient Q in this system is $Q = [ ext{Ca}^{2+}][ ext{C}2 ext{O}4^{2-}].$
- Precipitation of CaC $2$ O $4$ occurs when $Q > K_{sp}.$
- The presence of calcium ions and oxalate ions exceeding the solubility product leads to solid calcium oxalate formation (kidney stones).
- Note: The transcript emphasizes that the law of mass action applies; the Q expression must reflect the actual activities (concentrations) of the species in solution.

Question 4: HIV protease peptide bond cleavage

Question: The peptide bond cleaved by HIV protease is between which two amino acid residues?
- A) PHE and ALA
- B) Pro and VAL
- C) VAL and ALA
- D) PHE and PRO
Correct answer: D.
Explanation:
- The peptide bond cleaved is between PHE (phenylalanine) on the N-terminus side and PRO (proline) on the C-terminus side.
- Other options contain one correct residue but pair with an incorrect partner; hence D is correct.

Key Concepts and Formulas to Note

HIV protease characteristics:
- Class: aspartyl protease; mechanism involves an aspartate side chain in catalysis.
- Structure: small (99 residues per subunit) homodimer; active site relevant for inhibitor design.
Mechanistic distinction:
- Antagonist: blocks the biochemical function of a protein it binds to (as with compound one inhibiting HIV protease).
- Agonist: activates a receptor to produce a biological response.
Drug design strategy:
- Use transition-state analogs and active-site knowledge to design potent inhibitors.
- Iterative synthesis of derivatives to improve potency and pharmacokinetic properties (e.g., half-life).
Pharmacokinetics and metabolism:
- In vivo half-life: $t_{1/2} = 1.8 ext{ h}.$
- Primary metabolism via CYP3A (Cytochrome P450 family).
- Major metabolite formed by deacylation of CH $_2$ R groups on the piperazine-containing moiety.
Side effects and safety:
- Prolonged use can lead to nephrotoxicity presenting as calcium oxalate kidney stones (CaC $2$ O $4$ ).
Chemistry and equilibrium concepts:
- Solubility product constant: $K{sp}$ for CaC $2$ O $_4$ .
- Reaction quotient: $Q = [ ext{Ca}^{2+}][ ext{C}2 ext{O}4^{2-}].$
- Precipitation condition: Q > K{sp} ightarrow ext{precipitation (CaC}2 ext{O}_4) ext{ occurs}.
Nomenclature and shorthand used in the material:
- PHE = phenylalanine; PRO = proline; ALA = alanine; VAL = valine.
Real-world relevance:
- Structure-based drug design in antiviral therapy; balancing potency, metabolic stability, and safety.
- Consideration of drug-drug interactions (e.g., CYP3A metabolism) and adverse effects (kidney stone risk).

Connections to Foundational Principles

Enzyme catalysis and inhibition:
- HIV protease aspartyl mechanism and how inhibitors mimic transition states or bind to the active site to block catalysis.
Stereochemistry and drug design:
- The existence of multiple chiral centers impacts the number of stereoisomers, influencing synthesis, stereoselectivity, and pharmacodynamics.
Pharmacokinetics and toxicology:
- Metabolic pathways (CYP3A) influence drug half-life and interaction profiles.
- Adverse effects can arise from changes in solubility equilibria and precipitation of metabolites or drug-derived compounds.
Chemical equilibria in physiology:
- Solubility product and ion interactions drive precipitation phenomena in biological fluids (e.g., kidney stone formation).

Summary Takeaways

HIV protease inhibition is a validated anti-HIV strategy; compound design leverages active-site chemistry and metabolic fate to optimize efficacy and safety.
Antagonist action (not agonist) on HIV protease reduces viral maturation by blocking enzyme catalysis.
Stereochemistry significantly affects the number of possible isomers; with five chiral centers, a maximum of 32 stereoisomers can exist.
Drug safety considerations include potential nephrolithiasis due to CaC $2$ O $4$ precipitation when the product of ion concentrations exceeds K $_{sp}$ .
The correct peptide bond target of HIV protease in this passage is between PHE and PRO, which underpins proteolytic processing in the viral polyprotein.